Stephens Inc. AR Purchases 86,411 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Stephens Inc. AR increased its stake in Bristol Myers Squibb by 55.9% in Q2, acquiring 86,411 additional shares, bringing its total holdings to 240,867 shares valued at approximately $11.15 million.
• Insider transactions revealed that EVP David V. Elkins sold 56,000 shares at an average price of $47.33, reducing his position by 25.07% to 167,379 shares.
• Bristol Myers Squibb's latest earnings report showed an EPS of $1.46, exceeding expectations, with revenue of $12.27 billion, representing growth of 0.6% compared to the prior year.

Stephens Inc. AR boosted its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 55.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 240,867 shares of the biopharmaceutical company's stock after purchasing an additional 86,411 shares during the quarter. Stephens Inc. AR's holdings in Bristol Myers Squibb were worth $11,150,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Trifecta Capital Advisors LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $25,000. REAP Financial Group LLC lifted its position in shares of Bristol Myers Squibb by 202.8% during the 2nd quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 428 shares during the period. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Bristol Myers Squibb during the 1st quarter valued at $31,000. Accent Capital Management LLC bought a new stake in shares of Bristol Myers Squibb during the 1st quarter valued at $33,000. Finally, CBIZ Investment Advisory Services LLC lifted its position in shares of Bristol Myers Squibb by 66.0% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 231 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the company's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the transaction, the executive vice president owned 167,379 shares of the company's stock, valued at $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.09% of the stock is currently owned by insiders.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $43.61 on Tuesday. Bristol Myers Squibb Company has a 12-month low of $42.96 and a 12-month high of $63.33. The business has a 50-day simple moving average of $46.03 and a two-hundred day simple moving average of $47.32. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. The stock has a market cap of $88.76 billion, a PE ratio of 17.58, a PEG ratio of 2.27 and a beta of 0.33.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The business had revenue of $12.27 billion during the quarter, compared to analysts' expectations of $11.32 billion. During the same quarter in the prior year, the firm earned $2.07 EPS. The business's revenue for the quarter was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.7%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb's dividend payout ratio is presently 100.00%.

Analysts Set New Price Targets

BMY has been the subject of a number of recent analyst reports. Dbs Bank upgraded Bristol Myers Squibb to a "moderate buy" rating in a research report on Thursday, October 2nd. Morgan Stanley restated a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Daiwa America downgraded Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Weiss Ratings restated a "hold (c-)" rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Finally, Citigroup restated a "neutral" rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and fourteen have issued a Hold rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of "Hold" and a consensus target price of $57.23.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.